{"entity":{"id":"paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025","kind":"paper","name":"HPV 16 and 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9 to 14 years compared with three doses of quadrivalent vaccine in women aged 18 to 25 years in Costa Rica (PRIMAVERA)","aka":[],"tldr":"In Guanacaste, one dose of the bivalent HPV vaccine in 620 girls gave antibody levels non-inferior to three quadrivalent doses in women for HPV 18 but not HPV 16, though almost every girl had antibodies to both after three years.","summary":"A non-randomised, open-label immunobridging trial in Guanacaste Province (NCT03728881) that gave one dose of bivalent HPV vaccine to girls aged 9 to 14 and three doses of quadrivalent vaccine to women aged 18 to 25, and compared antibody concentrations at 36 months, to support a single-dose indication for the bivalent vaccine. Funded by the National Cancer Institute, Cancer Research UK and the Gates Foundation.","asOf":"2026-11-11","links":[{"label":"DOI","url":"https://doi.org/10.1016/S1473-3099(25)00284-1"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40683285/"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["hpv-bivalent-vaccine"],"companies":[],"institutions":["acib-funin-costa-rica","nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Lancet Infectious Diseases","year":2025,"doi":"10.1016/S1473-3099(25)00284-1","pmid":"40683285","authors":"Cortés B, Ocampo R, Porras C, Liu D, et al.","paperType":"translational","findings":["620 girls and 620 women were enrolled between April and August 2019.","At 36 months the HPV 16 antibody ratio was 0.50 (96% CI 0.44 to 0.57), not non-inferior; the HPV 18 ratio was 1.11 (96% CI 0.95 to 1.29), non-inferior.","99.8% of girls were seropositive for HPV 16 and 98.9% for HPV 18."],"whatItMeans":"Antibody levels alone did not meet the bar for changing the vaccine's label to one dose, which is why trials measuring protection directly, such as ESCUDDO, were needed.","caveats":["Not randomised, and it measures antibodies rather than protection from infection."],"participants":1240},"route":"/key-papers/paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"drug":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/"}],"institution":[{"id":"acib-funin-costa-rica","kind":"institution","name":"Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN)","route":"/institutions/acib-funin-costa-rica/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}]}}